/

Alpha Teknova, Inc.

TKNO US

TKNO USAlpha Teknova, Inc.

United States Composite

1.90

USD

+0.02

(+1.06%)

-1.38EPS Dil.

-1.38P/E

77.38MMarket Cap

Next Earnings

November 9

Held by Insiders

11.46%

Held by Institutions

77.36%

Short % of Float

0.13%

YTD Yield

-14.69%

Capital Structure

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

114

Working Capital

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

0.00%

10.81%

Net Income, GAAP

-NaN%

-370.00%

Free Cash Flow

-NaN%

-93.10%

Total Cash Common Dividend

- -

Total Equity

0.00%

-30.07%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.03

-0.52

-0.12

-0.13

-0.61

2022

-0.20

-0.22

-0.80

-0.47

-1.69

2023

-0.31

-0.25

-0.34

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Stephen Gunstream
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Address: 2290 Bert Drive Hollister CA United States 95023
CIK: 0001850902
Website: www.teknova.com
Business: Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.

Company News

tipranks.com
4 days ago
Buy Rating Affirmed for Alpha Teknova Amid Strong Q1 Performance and Strategic Cost Reductions
GuruFocus.com
10 days ago
Teknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy Development
GuruFocus.com
18 days ago
Teknova to Report First Quarter 2024 Financial Results on May 13, 2024
Zacks
23 days ago
Down -28.04% in 4 Weeks, Here's Why Alpha Teknova (TKNO) Looks Ripe for a Turnaround
Yahoo
2 months ago
Alpha Teknova, Inc. (NASDAQ:TKNO) Q4 2023 Earnings Call Transcript
Tipranks
2 months ago
Buy Rating on Alpha Teknova Reinforced by Strong Management and Conservative Growth Outlook
Yahoo
2 months ago
Alpha Teknova Inc (TKNO) Faces Revenue Decline Amid Market Challenges
Yahoo
2 months ago
Teknova Reports Fourth Quarter and Full Year 2023 Financial Results

Company News

tipranks.com
4 days ago
Buy Rating Affirmed for Alpha Teknova Amid Strong Q1 Performance and Strategic Cost Reductions
GuruFocus.com
10 days ago
Teknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy Development
GuruFocus.com
18 days ago
Teknova to Report First Quarter 2024 Financial Results on May 13, 2024
Zacks
23 days ago
Down -28.04% in 4 Weeks, Here's Why Alpha Teknova (TKNO) Looks Ripe for a Turnaround
Yahoo
2 months ago
Alpha Teknova, Inc. (NASDAQ:TKNO) Q4 2023 Earnings Call Transcript
Tipranks
2 months ago
Buy Rating on Alpha Teknova Reinforced by Strong Management and Conservative Growth Outlook
Yahoo
2 months ago
Alpha Teknova Inc (TKNO) Faces Revenue Decline Amid Market Challenges
Yahoo
2 months ago
Teknova Reports Fourth Quarter and Full Year 2023 Financial Results